SB1102 creates new requirements for pharmacy benefit managers, health insurers, and utilization review agents regarding prescription drug coverage and formulary changes. The bill generally prohibits a PBM or insurer from removing or limiting coverage for a prescription drug that was previously approved for a covered person during the remainder of that person’s health plan year, so long as the person remains enrolled in the same plan. It also bars switching a patient off a previously covered drug when the prescribing provider gives notice that the patient should continue the current medication.
The bill requires advance notice of at least 60 days before a formulary change that limits or excludes a drug, and that notice must explain how the provider can request continued coverage. It also establishes a formal formulary exception process at renewal, including response deadlines of 72 hours for standard requests and 24 hours for exigent circumstances. For certain patients who were already approved for a nonformulary drug under the same plan, the bill requires approval of an exception if specified clinical criteria are met, including prior failure of a formulary alternative, therapeutic benefit from the requested drug, and contraindication or serious adverse reaction to alternatives.
In practical terms, the bill amends Arizona insurance law in Title 20 and applies only to pharmacy benefit managers subject to existing PBM regulation under section 20-3333. It defines key terms such as “limit or exclude coverage,” “formulary exception,” and “exigent circumstances,” and it gives the Department of Insurance authority to enforce violations. The act applies to contracts, policies, or coverage renewed, amended, extended, or entered into on or after December 31, 2025.
The overall sentiment around the bill appears strongly supportive and largely noncontroversial. It advanced through both chambers with unanimous or near-unanimous votes at each recorded stage, including 26-0 in the Senate and 58-0 in the House on third reading. Committee actions also show broad support, with no recorded opposition in the vote history provided.
The main policy issue underlying the bill is the balance between patient continuity of care and insurer/PBM formulary management. Supporters likely viewed the bill as protecting patients who are stable on existing medications from disruptive coverage changes, while preserving some flexibility for formulary management and manufacturer-driven drug removals. Potential points of contention, though not reflected in the vote totals, would center on administrative burden, prior authorization and exception procedures, and whether the bill constrains cost-control tools used by insurers and PBMs.
SB1102 adds new statutory protections in Arizona insurance law for patients using prescription drugs covered through pharmacy benefit managers and health insurers. It restricts mid-year formulary changes for previously approved medications, requires advance notice to patients and prescribers, and mandates a structured exception process with specific timelines and clinical criteria. The bill also authorizes enforcement by the state insurance director under existing PBM enforcement provisions. Its practical effect is to increase continuity of prescription drug coverage and limit abrupt coverage disruptions for insured patients.
The bill appears to have had overwhelmingly positive reception in both the Senate and House, with unanimous or near-unanimous votes at every recorded stage. There is no evidence in the provided materials of organized opposition or significant floor controversy. The voting pattern suggests broad bipartisan agreement that the measure addresses patient access and continuity of care concerns.
The central tension in SB1102 is between patient access to stable medication regimens and the ability of insurers and pharmacy benefit managers to manage formularies, costs, and utilization. Critics of similar measures often argue that such rules can reduce flexibility, increase administrative work, and limit cost-saving formulary changes, while supporters emphasize that patients should not be forced off effective medications mid-year. The bill partially addresses that balance by allowing formulary additions, manufacturer-driven removals, and changes for patients not already on a previously approved drug, but it still imposes significant notice and exception requirements on PBMs and insurers.